Retractable Technologies Inc. (RVP) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.56 -1.96% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.56

Retractable Technologies Inc. (RVP) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $16.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVP Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is RVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Retractable Technologies Inc. (NYSE: RVP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.56 (-1.96% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RVP ranks #773 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does RVP compare to MODD and PAVM in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), RVP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.1%, and ROIC of -23.3%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and PAVM (PAVmed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M). Among the 5-stock peer group, RVP leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVP?
β–Ό

Per RVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000946563), Retractable Technologies Inc. generated $38.3M in revenue (+15.8% YoY), -$12.6M in net income, and -$7.1M in free cash flow against $142.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.56 (-0.54%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (5)Whales (11)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$1 Bull$0 Base$0 Bear
πŸ“¬ FREE RVP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for RVP)Realized 20D OHLCV Swing Band: Β±5.3%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY RVP SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (Β±5.3% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 25 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
39
Grade E$0.61-4.9% Next Q
Q2 (-2Q)
36
Grade E$0.58+1.7% Next Q
Q3 (-1Q)
34
Grade E$0.59-5.1% Next Q
Current
31
Grade E$0.56-9.4% Hist 90D Ξ±
Trajectory: E (39) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a RVP Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While RVP currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.59) forces dealer call-delta covering toward $0.95.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVPβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œRVP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

RVP Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RVP)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RVP. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RVP)

  • βœ“Walkthrough of RVP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RVP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.85%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.57H $0.57L $0.56C $0.56VOL 33.3K
RES: $0.73SUP: $0.56SMA50: $0.66SMA200: $0.68
$0.78$0.72$0.66$0.60$0.54RES $0.73SUP $0.56$0.562026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RVP today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for RVP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RVP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVP)

Health Care Rank #773 of 1016 βš”οΈ MODD vs RVP Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (RVP vs. MODD, PAVM, CTSO, PMI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Retractable Technologies Inc. (RVP) ranks #773 by composite RQD confidence (31/100, grade E) and #840 by equity capitalization ($16.9M). Within this direct 5-issuer industry benchmark cohort, RVP leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RVP at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RVP ACTIVE
Retractable Technologies Inc.
E 31/100 β€” 0.1% -23.3% -1.96% $16.9M Benchmark Subject
MODD
Modular Medical Inc.
E 33/100 β€” β€” -35.0% 0.00% $16.3M /modd-vs-rvp β†’
PAVM
PAVmed Inc.
E 28/100 β€” -30.0% -35.0% -1.01% $15.6M /pavm-vs-rvp β†’
CTSO
Cytosorbents Corporation
E 22/100 β€” 71.5% -35.0% +3.18% $14.3M /ctso-vs-rvp β†’
PMI
Picard Medical Inc.
D 48/100 β€” β€” β€” +2.96% $20.5M /pmi-vs-rvp β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000946563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Retractable Technologies Inc. (RVP) reported GAAP revenue of $38.3M (+15.8% vs. FY2024 revenue of $33.0M , and -12.2% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$7.1M, and free cash flow of -$7.1M (+45.6% YoY). On the balance sheet, RVP closed FY2025 with $142.6M in total assets against $0 in total debt (Altman Z-Score: 0.52, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $38.3M -$12.6M -$7.1M -$7.1M $142.6M β€”
FY2024 (FY) 2024-12-31 $33.0M -$11.9M -$11.6M -$13.0M $160.7M $900.0K
FY2023 (FY) 2023-12-31 $43.6M -$7.0M $2.8M $2.8M β€” β€”

3. RVP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Retractable Technologies Inc. (NYSE: RVP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.56 (-1.96% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RVP ranks #773 in composite RQD confidence.

How does RVP compare to MODD and PAVM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RVP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.1%, and ROIC of -23.3%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and PAVM (PAVmed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M). Among the 5-stock peer group, RVP leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVP?

Per RVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000946563), Retractable Technologies Inc. generated $38.3M in revenue (+15.8% YoY), -$12.6M in net income, and -$7.1M in free cash flow against $142.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVP trading relative to its 50-day, 200-day, and 52-week technical levels?

RVP last traded at $0.56 (-1.96% on volume of 33,280 shares), positioning the stock -15.15% below its 50-day simple moving average ($0.66) and -17.65% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.56 to $0.90, RVP sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of Β±5.3% ($1.00 to $0.59).

RVP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are RVP insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RVP leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

ROARABLE RATING BRIEF β€’ RQD 31/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

RVP β€” Retractable Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:50:15Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RVP scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." The five pillars are:

  • Fundamental cash engine: 5 / 20. Per the RQD rating, ROIC is -23.3% and FCF yield is 0%. For an investor, this means the business is not currently generating cash returns on invested capital, so any upside must come from a change in operating performance rather than from existing earnings power.
  • Whale 13F flow: 11 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar relative to its weight, and it is the main offset to the weaker scores elsewhere, though the source data does not itemize the underlying holdings.
  • Insider conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow, and the score is the weakest of the five. For an investor, this indicates limited insider-driven confidence signals in the available data.
  • Macro regime fit: 7 / 20. Per the RQD rating, beta is 1.0 and the score reflects sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the market, so it offers no defensive cushion from its beta alone.
  • Forensic balance sheet: 5 / 20. Per the RQD rating, the Altman Z-Score is 0.52, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. These readings point to financial distress risk, which is the primary driver of the "Forensic Risk" verdict.

Valuation tradeoffs are difficult to frame because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data, so the investor cannot benchmark the $0.58 price against earnings. The upside case rests on a turnaround in operating margin from -55.3%, while the downside case is reinforced by the weak forensic readings. The sub-$1 price and $17.3M market capitalization indicate a micro-cap profile with correspondingly limited liquidity (daily volume of 17,484).

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$38.3M$-21.2M$-12.6MN/A$-7.1M$2.6MN/A
FY 2024$33.0M$-21.1M$-11.9MN/A$-13.0M$4.2M$0.9M
FY 2023$43.6M$-11.5M$-7.0MN/A$2.8MN/AN/A

Per the SEC financials, revenue moved from $43.6M in FY 2023 to $33.0M in FY 2024 and then recovered to $38.3M in FY 2025, while net losses persisted in all three periods. Per the market data, gross margin is 0.1%, operating margin is -55.3%, and net margin is -32.8%, with ROIC at -23.3%. Per the RQD rating, the Altman Z-Score is 0.52 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Per the SEC financials, cash fell from $4.2M to $2.6M across FY 2024 to FY 2025, and debt is reported as N/A for FY 2025.

Recent Catalysts & News Wire Analysis

The news wire contains six items, each tagged YELLOW and MARKET WIRE, from sources including Yahoo Finance UK, TradingView, Stock Titan, TradingKey, and Yahoo! Finance Canada. The headlines describe seasonal returns charts, estimates coverage, a 1.96% slip to $0.56 described as testing the lower end of the range, a "Max Pain Level" reference, and inclusion in a list of top U.S. stock losers. None of the items reports a fundamental event such as earnings, guidance, or a corporate action. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no butterfly links. Key risk watch items are the lower-end price test and the continued decline on the loser list.

Open Questions

  • What products and customers generate the $38.3M in FY 2025 revenue, and what drove the decline from $43.6M in FY 2023?
  • What is the reported debt level in FY 2025, given that the filing shows N/A?
  • What is the basis for the 11/20 whale 13F pillar score, given that no holder data is itemized?
  • What drove the insider conviction score of 3/20, and which Form 4 or Congressional trades make up the cluster flow?
  • How does the company plan to close the -55.3% operating margin gap, and what is its cash runway given $2.6M in cash?

RVP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Retractable Technologies Inc. (RVP) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to RVP Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVP Bull vs. Bear Conversation Board β€” What's Your Call at $0.56?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVP 🐻 67% BEARISH CONVICTION
1. Pick Your Side on RVP:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.51 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is RVP (E β€’ RQD 31/100) a Buy at $0.58?

Welcome to the RVP (Retractable Technologies Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.45 (-22.4%)
Spot @ $0.58

Pump the brakes on RVP β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RVP, but look at what you are paying: current EV/EBITDA multiples with 0.1% gross margins. Unless Retractable Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $0.70 (+20.7%)
Spot @ $0.58

RVP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RVP, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.58 (52-wk range $0.57 - $0.91), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%